about
Comprehensive mutational profiling of core binding factor acute myeloid leukemia.IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association.Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors.Down-syndrome-like acute megakaryoblastic leukemia in a patient with Cornelia de Lange syndrome.Posttransplantation relapse of pediatric chronic myelomonocytic leukemia cured using donor lymphocyte infusion.Detection of a new heterozygous germline ETV6 mutation in a case with hyperdiploid acute lymphoblastic leukemia.Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.Quantification of EVI1 transcript levels in acute myeloid leukemia by RT-qPCR analysis: A study by the ALFA Group.Clonal interference of signaling mutations holds prognostic relevance in core binding factor acute myeloid leukemia.Classification of CEBPA mutated acute myeloid leukemia by GATA2 mutations.Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group.Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemiaMolecular prognostic factors in acute myeloid leukemia receiving first-line therapy with azacitidineRestoration of hematopoiesis in a case of myelodysplastic syndrome associated with systemic lupus erythematosus treated with rituximabMinimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNAGenetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemiaPolycomb repressive complex 2 haploinsufficiency identifies a high-risk subgroup of pediatric acute myeloid leukemiaImpact of Wilms' tumor 1 expression on outcome of patients undergoing allogeneic stem cell transplantation for AMLMyelodysplastic syndrome (MDS) with isolated trisomy 8: a type of MDS frequently associated with myeloproliferative features? A report by the Groupe Francophone des MyélodysplasiesOutcomes and mutational analysis of patients with lower-risk non-del5q myelodysplastic syndrome treated with antithymocyte globulin with or without ciclosporine A
P50
Q33758306-63D26255-B129-49B6-AC9A-616DB1A33E99Q36561772-99801C08-FAB2-455A-A410-7281BA0E3DE2Q38263126-DD30B1C4-2BA7-4511-B6AD-A4431E9300E5Q47174443-4FD8ED2F-0CF3-4986-94C9-C8C0AD53C56AQ48088016-9F9792A4-6D69-4284-A086-F221D3FFEFE1Q48184463-3AE400C4-355E-4E39-ABB1-9FF3F9A2CB4AQ51215501-DBE94943-2825-48C8-82C0-988098A56AA4Q53311179-8CE86664-AFA1-465F-8740-C51968ECB714Q54114465-B41C3AFE-1A1B-437B-BEFD-759CBD6864DBQ54295293-836F2D32-79CB-4254-811D-4ED40862CE99Q55279705-B3D0F6E7-673A-4B65-9FFB-68AEA0504B36Q84261845-426FE251-BB94-4C5B-87C9-58DA4C6974C1Q86729833-8A6BA551-02DB-46AB-9EC9-2EAEBB18B0C8Q87063210-CF0DF226-1002-4E07-90DE-ECA508E70CA7Q87421398-834A038E-21D5-4819-A760-F9F16ECFCE2BQ88609392-5C2B4284-3A40-4762-8CCD-67F2632A95AAQ89297785-7785C885-9FC1-4EA2-892B-8A75635EE759Q89483800-98E815FF-1894-410D-9209-E049348EEB28Q90025325-510BCB84-EF73-4F15-A483-F9C06C7A527FQ90343269-5E9A6C3A-EA77-467C-A496-46714E3AEBEA
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-3197-0785
@en
name
Alice Marceau-Renaut
@ast
Alice Marceau-Renaut
@en
Alice Marceau-Renaut
@es
Alice Marceau-Renaut
@nl
type
label
Alice Marceau-Renaut
@ast
Alice Marceau-Renaut
@en
Alice Marceau-Renaut
@es
Alice Marceau-Renaut
@nl
prefLabel
Alice Marceau-Renaut
@ast
Alice Marceau-Renaut
@en
Alice Marceau-Renaut
@es
Alice Marceau-Renaut
@nl
P106
P21
P31
P496
0000-0002-3197-0785